New pill battles blood disorder in Head-to-Head trial
NCT ID NCT05020652
Summary
This study is testing whether a new oral drug called TQ05105 is better than the standard drug hydroxyurea at controlling moderate to high-risk myelofibrosis, a serious bone marrow disorder. It involved 107 patients who were randomly assigned to receive one of the two treatments. The main goal is to see if the new drug can shrink enlarged spleens and ease symptoms more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AND HIGH RISK MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510055, China
-
Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, 300020, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
-
West China School of Medicine / West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.